Crispo Anna, Montagnese Concetta, Perri Francesco, Grimaldi Maria, Bimonte Sabrina, Augustin Livia Silvia, Amore Alfonso, Celentano Egidio, Di Napoli Marilena, Cascella Marco, Pignata Sandro
Epidemiology and Biostatistics Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.
Head and Neck Medical and Experimental Oncology Unit, Istituto Nazionale Tumori, IRCCS Fondazione G. Pascale, Naples, Italy.
Front Oncol. 2020 Aug 11;10:1571. doi: 10.3389/fonc.2020.01571. eCollection 2020.
Italy and worldwide are experiencing an outbreak of a new coronavirus-related disease, named COVID-19, declared by the WHO COVID-19 a pandemic. The fragility of cancer patients is well-known, with many cases affecting aged patients or those with several comorbidities that frequently result in a loss of independency and functionality. Therefore, cancer patients have been greatly affected by this health emergency and, due to their vulnerability to COVID-19, oncologic patient visits have been often delayed or canceled leading to possible under-treatment. Different solutions can be adopted for reducing travels to cancer screening centers and the overall impact of cancer screening visits. As a consequence, it has been recommended that, when possible, the follow-up visits for cancer patients treated with oral anticancer drugs could be performed telematically. Furthermore, many patients refuse hospital visits, even if necessary, because of fear of contagion. Moreover, in some regions in Italy even the very first non-urgent visits have been postponed with the consequent delay in diagnosis, which may negatively affect disease prognosis. For these reasons, new approaches are needed such as the telemedicine tool. Throughout organized and appropriate tools, it would be possible to manage patients' visits and treatments, to avoid the dangerous extension of waiting lists when the standard activities will resume. In this context, a number of hospital visits can be substituted with visits at small local health centers, and general practitioners'office, taking in turn, advantage of well-defined telemedicine path which will be developed in the post-emergency phase.
意大利乃至全球都在经历一种由新型冠状病毒引发的疾病的爆发,该疾病名为COVID-19,世界卫生组织宣布COVID-19为大流行病。癌症患者的脆弱性是众所周知的,许多病例影响老年患者或患有多种合并症的患者,这些合并症经常导致独立性和功能丧失。因此,癌症患者受到了这场卫生紧急事件的极大影响,并且由于他们对COVID-19的易感性,肿瘤患者的就诊经常被推迟或取消,从而导致可能的治疗不足。可以采用不同的解决方案来减少前往癌症筛查中心的次数以及癌症筛查就诊的总体影响。因此,建议在可能的情况下,对接受口服抗癌药物治疗的癌症患者的随访可以通过远程方式进行。此外,许多患者即使有必要也拒绝去医院就诊,因为害怕被传染。此外,在意大利的一些地区,甚至最初的非紧急就诊也被推迟,从而导致诊断延迟,这可能会对疾病预后产生负面影响。出于这些原因,需要新的方法,如远程医疗工具。通过有组织且合适的工具,将有可能管理患者的就诊和治疗,以避免在标准活动恢复时等待名单危险地延长。在这种情况下,可以用在当地小型医疗中心和全科医生办公室的就诊来替代一些医院就诊,同时利用在紧急情况后阶段将开发的明确的远程医疗路径。